Autopsy report · NCT05220098

First-in-Human Study of TAK-280 in Participants With Solid Tumors

“Terminated due to limited anti-cancer activity”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 months before it started.
• Ran for about 3 years 3 months before it stopped.
• 69 participants enrolled.
• Results were posted on the registry 11 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

Takeda

Sponsor type

Industry

Conditions

Unresectable Locally Advanced or Metastatic Cancer

Interventions

TAK-280

Participants

69

Sites

23

Countries

Australia, Canada, Spain, United States

Trials that died the same way

• Vorinostat, Carboplatin and Gemcitabine in Women With Recurrent, Platinum-Sensitive Ovarian Cancer
  “Terminated due to unacceptable toxicity” (73% match in meaning)
• Pemetrexed and Cisplatin as Treatment in Small Cell Lung Cancer
  “Terminated due to lack of efficacy” (72% match in meaning)
• A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma
  “Terminated due to dose limiting toxicity” (71% match in meaning)
• QUILT-3.031: AMG 337 in Subjects With Advanced or Metastatic Clear Cell Sarcoma
  “Prematurely terminated due to lack of therapeutic effect” (70% match in meaning)
• Umbralisib and Pembrolizumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
  “Company providing drug terminated their oncology program” (68% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.